Abstract:Abstract Purpose Our aim was to characterize the newly established new drug conditional approval process in China and discuss the challenges and opportunities with respect to new drug research and development and registration. Methods We examined the new approval program through literature review, law analysis, and data analysis. Data were derived from published materials, such as journal articles, government publications, press releases, and news articles, along with statistical data from INSIGHT-China Pharma Databases, the China Food and Drug Administration website, the Center for Drug Evaluation website, the US Food and Drug Administration website, and search results published by Google. Findings Currently, there is a large backlog of New Drug Applications in China, mainly because of the prolonged review time at the China Food and Drug Administration, resulting in a lag in drug approvals. In 2015, the Chinese government implemented the drug review and registration system reform and tackled this issue through various approaches, such as setting up a drug review fee system, adjusting the drug registration classification, and establishing innovative review pathways, including the conditional approval process. Implications In Europe and the United States, programs comparable to the conditional approval program in China have been well developed. The conditional approval program recently established in China is an expedited new drug approval process that is expected to affect new drug development at home and abroad and profoundly influence the public health and the pharmaceutical industry in China. Like any program in its initial stage, the conditional approval program is facing several challenges, including setting up a robust system, formatting new drug clinical research requirements, and improving the regulatory agency’s function for drug review and approval. The program is expected to evolve and improve as part of the government mandate of the drug registration system reform.

Discussion on the Major Changes of Drug Administration Acceptance Review and Approval System

On the Amendments of China’s Provisions for Drug Registration

Administrative Law Reform of Drug Review Regime in China

Development and Reform of the Drug Administration System in China

Overview on the Amendments of Provisions for Drug Registration in China

Comparison of Marketing Authorization System for Drug Wholesale Enterprises between China and America

Comparisons on New Drug Technical Review Between SFDA and FDA

Re-discussion on Newly Added Examination and Approval System of Medical Material

Research on priority review of new drugs in China

Overview of Drug Evaluation System in China

The New Drug Conditional Approval Process in China: Challenges and Opportunities

Performance appraisal system of new drug review in Japan and its reference to China

Recent Advances in Drug Development and Regulatory Science in China

Reform of Non-administrative Licensing Approval：Reviewing and Responding

Macroscopic reflections on China’s drug supervision system in transition

The changing landscape of clinical trial and approval processes in China

Discussion on the Current Situations and Problems of Chinese Counterfeited & Inferior Drug Regulation

Approvals of Pharmaceutical Drugs in China in the Post-Drug Registration Regulation II Era.

Explanation and Analysis the 81~(st) Provision of Drug Administration Law Implementing Rules

Amend the Pharmaceutical Administration Law, strengthen the linkage mechanism of drug administrative organs and criminal justice agencies

Evaluation on New Drug Registration System in America and Its Illumination for China